Some of these are localized to certain geographical areas (eg, p.R451W in CYP11A1 in eastern Turkey, c.IVS3ds+1delG in MRAP in western Turkey), which could lead to focused cost-effective clinical genetic testing for patients and families at risk of adrenal insufficiency in these regions (Figure 3A). This evidence concerns the gene CYP11A1 and Adrenal insufficiency.